Ayman Jamal, MD
Cardiovascular Disease · Phoenix, AZNPI 1083600845
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,530 of the $42,090 with a category attached, or 60.7%. Cardiovascular Systems Inc. accounts for 62.2% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $17,803 and has fallen 79.6% since, to $3,638 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $143.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$26K
- Abbott$3K
- Celonova Biosciences, Inc.$3K
- Medtronic$2K
- Edwards Lifesciences$2K
- Abiomed$1K
- plus $5K from 34 others
Across 17 payments — averaging $2074.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$15K
- Cardiovascular Systems Inc.$15K
- Abbott$5K
What the payments were for
- Consulting fees$2,4006%
- Speaking & faculty fees$25,53061%
- Travel & lodging$1,3813%
- Food & beverage$12,71930%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 26 | $26,181 |
| Abbott | 59 | $3,104 |
| Celonova Biosciences, Inc. | 3 | $2,633 |
| Medtronic(2 entities) | 31 | $1,915 |
| Edwards Lifesciences | 28 | $1,703 |
| Abiomed | 20 | $1,268 |
| Boston Scientific | 23 | $884 |
| Biosense Webster, Inc. | 15 | $579 |
| W. L. Gore & Associates, Inc. | 3 | $403 |
| Penumbra, Inc. | 3 | $382 |
| Bolton Medical Inc | 4 | $299 |
| Inspiremd Ltd | 3 | $241 |
| Cleerly, Inc. | 8 | $240 |
| Kaneka Medical America LLC | 1 | $199 |
| Atricure, Inc. | 4 | $197 |
| AstraZeneca | 5 | $189 |
| Endologix LLC | 2 | $188 |
| Novartis | 8 | $159 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $149 |
| Pfizer | 7 | $131 |
| Heartflow, Inc. | 1 | $121 |
| Angiodynamics, Inc. | 1 | $119 |
| Boehringer Ingelheim | 4 | $118 |
| Baxter Healthcare | 3 | $100 |
| Johnson & Johnson | 3 | $74 |
| Kestra Medical Technology Services, Inc. | 3 | $69 |
| Novo Nordisk | 3 | $68 |
| Surmodics, Inc. | 1 | $64 |
| Merck | 3 | $62 |
| Saranas, Inc. | 1 | $46 |
| Amgen | 2 | $32 |
| Cvrx, Inc. | 1 | $23 |
| ZOLL Respicardia, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Philips North America LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Cook Medical LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Coronary Orbital Atherectomy System$20,218
- Diamondback Coronary$5,733
- TRICLIP$838
- Impella$673
- Edwards SAPIEN 3 Transcatheter Heart Valve$533
- MitraClip$531
- CoreValve Evolut$477
- COREVALVE EVOLUT R$375
- WATCHMAN Access System$267
- AVVIGO Guidance System$250
- Indigo System$239
- Micra$238
- GORE TAG Conformable Thoracic Endoprosthesis$168
- CGuard Prime Carotid Stent System$159
- AMPLATZER Occluders$154
- Peripheral Orbital Atherectomy System$154
- TREO ABDOMINAL STENT-GRAFT SYSTEM$152
- Torus Stent Graft System$146
- ENDOCROSS Device$146
- GORE TAG Thoracic Branch Endoprosthesis$143
How this compares
$42,090 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 289 | $354,688 |
| EntrestoSacubitril/Valsartan | 115 | $169,578 |
| FarxigaDapagliflozin Propanediol | 125 | $127,472 |
| Repatha SureclickEvolocumab | 54 | $58,532 |
| XareltoRivaroxaban | 27 | $44,170 |
| JardianceEmpagliflozin | 38 | $43,619 |
| BrilintaTicagrelor | 36 | $33,690 |
| MultaqDronedarone Hcl | 14 | $17,899 |
| Metoprolol Succinate | 582 | $7,703 |
| Ranolazine ErRanolazine | 46 | $6,545 |
| Atorvastatin Calcium | 593 | $6,139 |
| Rosuvastatin Calcium | 269 | $4,314 |
| ClopidogrelClopidogrel Bisulfate | 302 | $3,906 |
| Carvedilol | 293 | $3,242 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 191 | $2,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $131 | $354,688289 claims |
| NovartisEntresto | $159 | $169,578115 claims |
| AstraZenecaFarxiga, Brilinta | $189 | $161,162161 claims |
| Johnson & JohnsonXarelto | $74 | $44,17027 claims |
| Boehringer IngelheimJardiance | $118 | $43,61938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
- Venkataramanan GangadharanPhoenix$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.